List view / Grid view
Pharmaceutical companies are under increasing pressure to get novel drugs to market as quickly as possible. Here, Sheraz Gul discusses how integrating processes could help streamline drug discovery in the future.
Monoclonal antibodies are used in a wide range of applications, such as basic research, biopharmaceutical development and in vitro diagnostics.
This In-Depth Focus features articles highlighting the importance of effective data management strategies as well as the recent trends in upstream bioprocessing.
In a recent study in mice, researchers have found a way to deliver specific drugs to parts of the body that are exceptionally difficult to access.
Target-driven drug discovery, in which the starting point is a specific protein target hypothesised to play an important role in disease, has been the dominant paradigm for the last few decades. However, phenotypic-driven drug discovery, which does not rely on a specific target hypothesis, is starting to regain traction for…
Sartorius Stedim Biotech (SSB), a leading international supplier for the biopharmaceutical industry announced the launch of the BIOSTAT® RM TX single-use bioreactor, a new wave mixed system developed specifically for closed, automated expansion of consistent quality cell products such as ex vivo cellular immunotherapies...
14 February 2019 | By Sartorius
The BIOSTAT® RM TX system consists of an automated control unit and a rocking platform, for gently agitating a single-use Flexsafe® RM bag...
Find out how to streamline Cell Line Development by identifying high-producing clones with monoclonality assurance in one day.
Development and production of biopharmaceuticals is complex. Even minor impurities, or changes in attributes such as glycosylation or charge heterogeneity, can have a profound impact on the safety and efficacy of the final product. Traditionally, multiple analytical techniques have been required to assess the full range of biopharmaceutical product attributes.…
Every day scientists are working to discover and develop new therapies and treatments to change the lives of patients suffering from serious and debilitating illnesses. Amgen Inc. has made it a priority to unlock the potential of biology to discover, develop, manufacture, and deliver innovative therapeutics to patients.
With breakthroughs in molecular engineering and antibody humanisation, monoclonal antibodies (mAb) are one of the fastest-growing classes of biopharmaceuticals for multiple clinical indications including cancer, cardiovascular disease, autoimmune disorders and infectious disease. Most therapeutic antibody candidates are initially generated using hybridoma technology or primary B-cell screening after antigen immunisation.
Many bioanalytical labs work with a crowded and siloed set of systems and processes. From part electronic to part paper-based workflows to standalone point-solutions, the result is a lack of insight into data and slower reporting and results handling.
The relative failure of molecular target-based drug discovery has led to a return to phenotypic screening. Targets that are intracellular necessitate their drug ligands to pass through plasma membranes, where the protein:lipid ratio is often 3:1 by mass and at least 1:1 by area. The widespread view that most of…
Researchers in Denmark have developed a method that enables better tailored pharmaceuticals with fewer side effects.
Explore the full kinetic and epitope diversity of large antibody libraries with high throughput Array SPR (Surface Plasmon Resonance).
